FDA Approves Three New Type2 Diabetes Therapies
Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
Deerfield, Ill., January 25, 2013, and Osaka, Japan, January 26, 2013 – Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.
“Takeda is pleased with the FDA approval of NESINA, OSENI and KAZANO for the treatment of type 2 diabetes, a therapeutic category in which we have more than twenty years of clinical and patient experience,” said Douglas Cole, president, Takeda Pharmaceuticals U.S.A., Inc. “Millions of people are affected by diabetes and, as a leader in the diabetes arena, Takeda is dedicated to working to advance patient care and helping to meet the needs of this growing patient population.”
to continue, click here
http://www.takeda.com/news/2013/20130126_5626.html
Tags: Takeda, Type2, algogliptin
Replies to This Discussion
-
Permalink Reply by lotsofshots on -
With names like NESINA, OSENI and KAZANO, sheesh, I would stick with the old stuff. It works just fine.
-
Permalink Reply by Brian (bsc) on -
Nesina (alogliptin) is a drug of the class DPP-4. Others include Januvia (sitagliptin), Onglyza (saxagliptin) and Gavus (vildagliptin)(approved in the EU, but not the US). These drugs inhibit the GLP-1 and GIP pathways and have been found to drop your A1c by about 0.5%. There are some who believe that the GLP-1 class of drugs are inherently more effective.
It is nice to see "competition." But this is a me too type of thing, we already have two expensive options, this is yet a third which is not any more effective than options already on the market. In fact, a real criticism is metformin monotherapy is more effective than DPP-4 monotherapy, but still I regularly hear of fellow patients put on these expensive medications as a first medication.
So, I greet this anouncement with a hearty "Whoop de doo."
Advertisement
REsources
Groups
From the Diabetes Hands Foundation blog...
How do you measure the work of volunteers?
329,040 minutes, 329,040 moments so dear. 329,040 minutes — How do you measure, measure volunteers? In smileys, in tears shed, in counsel, in cups of coffee. In units, in carb counts, in laughter, in strife. In 329,040 minutes – how …Continue Reading
DHF Expands Board of Advisors
Diabetes Hands Foundation has always relied on partners and advisors to increase its understanding of the diabetes space, in order to better serve people touched by diabetes. Today this is as true as ever, as we proudly announce the expansion …Continue Reading
TuDiabetes Team
DHF STAFF
 Manny Hernandez(Co-Founder, Editor, has LADA)
|
DHF VOLUNTEERS
Lead Administrator
 Bradford (has type 1) |
Administrators
 Lorraine (mother of type 1) |
 Marie B (has type 1) |
|
|
|
|
|
|
LIKE us on Facebook
Spread the word
This site complies with the HONcode standard for trustworthy health information: verify here.
© 2013 A community of people touched by diabetes, run by the Diabetes Hands Foundation.
